These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37120972)

  • 1. Separation and structural characterization of unknown impurity in vancomycin by two-dimensional preparative liquid chromatography, LC-MS and NMR.
    Wang X; Qiu Y; Wen H; Weng R; Chen D; Liu H
    J Pharm Biomed Anal; 2023 Aug; 232():115403. PubMed ID: 37120972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of unknown impurities in Coenzyme Q
    Deng Y; Chen X; Wang L; Peng X; Lin M
    J Pharm Biomed Anal; 2019 Oct; 175():112771. PubMed ID: 31330281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two unknown impurities in roxithromycin by 2D LC-QTOF/MS/MS and NMR.
    Wang J; Zhou J; Xu Y; Zhu B; Jin Y
    J Pharm Biomed Anal; 2020 May; 184():113196. PubMed ID: 32113121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS.
    Raman B; Sharma BA; Ghugare PD; Karmuse PP; Kumar A
    J Pharm Biomed Anal; 2009 Oct; 50(3):377-83. PubMed ID: 19556091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and identification of a major impurity in a new bulk drug candidate by preparative LC, ESI-MS(n), LC-MS-MS, and NMR.
    Li N; Yang J; Qin F; Li F; Gong P
    J Chromatogr Sci; 2007 Jan; 45(1):45-9. PubMed ID: 17254383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel process-related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR.
    Zhu P; Yang W; Hong L; Cheng Q; Luo L; He J; Chen J
    J Pharm Biomed Anal; 2015 Mar; 107():437-43. PubMed ID: 25666544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of thermal degradation impurity in brimonidine tartrate by HPLC, LC-MS/MS, and 2DNMR.
    Baksam V; Nimmakayala S; Devineni SR; Muchumarri RMR; Shandilya S; Kumar P
    J Pharm Biomed Anal; 2021 Oct; 205():114297. PubMed ID: 34391137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Structural Elucidation of New Process Impurity in Testosterone.
    Gupte V; Luthra U; Desai N
    J Chromatogr Sci; 2018 May; 56(5):403-408. PubMed ID: 29554236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Separation and identification of impurities from intermediates of istradefylline].
    Wang Y; Lü X; Xu H; Meng Z; Li J; Xu Z; Xue M
    Se Pu; 2021 Apr; 39(4):430-436. PubMed ID: 34227764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of the impurity in auramine O by high performance liquid chromatography-ion trap-time of flight mass spectrometry and preparation of the auramine O reference standard by preparative high performance liquid chromatography].
    Che F; Lu Y; Xi X; Lan T; Wei Y
    Se Pu; 2019 Mar; 37(3):299-304. PubMed ID: 30900859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
    Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
    J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, Isolation, and Characterization of a Novel Degradation Impurity of Busulfan Using Preparative Chromatography, NMR, and LC-MS.
    Yerla RR; Manubolu Surya SB
    J AOAC Int; 2024 Jul; 107(4):582-591. PubMed ID: 38430462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
    Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.